Research programme: dendritic cell monoclonal antibodies - Alexion AstraZeneca Rare Disease/UMC Nijmegen
Alternative Names: Anti-DC-SIGN antibodies; Anti-L-SIGN antibodies; Cancer vaccine - Alexion AstraZeneca Rare Disease/UMC NijmegenLatest Information Update: 29 Jul 2021
Price :
$50 *
At a glance
- Originator University Medical Centre of Nijmegen
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 30 Jan 2007 Preclinical development is ongoing for Cancer
- 29 Sep 2005 This programme is still in active development